Treatment of invasive fungal infections in immunocompromised and transplant patients: AmBiLoad trial and other new data (Q33384785)

26 July 2017

1 reference

title

Treatment of invasive fungal infections in immunocompromised and transplant patients: AmBiLoad trial and other new data (English)

1 reference

invasive fungal infections

26 July 2017

main subject

1 reference

Jesus Guinea

2

0 references

Emilio Bouza

object named as

Emilio Bouza

series ordinal

4

0 references

Patricia Muñoz

series ordinal

1

object named as

Patricia Muñoz

1 reference

26 July 2017

3

Marta Torres Narbona

1 reference

26 July 2017

publication date

1 November 2008

1 reference

International Journal of Antimicrobial Agents

26 July 2017

published in

1 reference

26 July 2017

volume

32 Suppl 2

1 reference

26 July 2017

page(s)

S125-31

1 reference

Workload due to Aspergillus fumigatus and significance of the organism in the microbiology laboratory of a general hospital.

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Severe cutaneous zygomycosis: evaluation of treatment with high doses of liposomal amphotericin B in a one-year old child

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Antifungal resistance in pathogenic fungi

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Treatment of solid organ transplant patients with invasive fungal infections: should a combination of antifungal drugs be used?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Interactions between triazoles and amphotericin B against Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Synergism of Polyene Antibiotics with 5-Fluorocytosine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Synergistic Action of Amphotericin B and 5-Fluorocytosine Against Yeast-Like Organisms

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Mechanisms of synergistic interactions between amphotericin B and flucytosine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Combined action of amphotericin B and 5-fluorocytosine on pathogenic yeasts susceptible to either drug alone.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Further evidence for sequential action of amphotericin B and 5-fluorocytosine against Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Reduction of nephrotoxicity associated with amphotericin B deoxycholate

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Combination echinocandin-polyene treatment of murine mucormycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial).

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970013-X

7 January 2021

10.1016/S0924-8579(08)70013-X

Identifiers

DOI

1 reference

26 July 2017

1 reference